On December 8, 2022, Hangzhou 1gene Technology Co., Ltd. closed the transaction. The company has received CNY 1,94,81,560 ($2,800,000) in its Series B round of funding led by new investor, ChengDa Pharmaceuticals Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
20.63 CNY | -0.72% | -7.36% | -18.88% |
1st Jan change | Capi. | |
---|---|---|
-18.88% | 434M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 301201 Stock
- News ChengDa Pharmaceuticals Co., Ltd.
- Hangzhou 1gene Technology Co., Ltd. announced that it has received CNY 19.48156 million in funding from ChengDa Pharmaceuticals Co., Ltd.